It was learned from the company that on April 15, Sun Dongsheng, vice governor of Heilongjiang Province, together with the leaders of provincial departments such as the Provincial Health Commission, went deep into the research and guidance of Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) pharmaceutical industry, and held in-depth discussions and exchanges with Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) director long Tonghua and relevant principals of the company on pharmaceutical industry policies, future development and responsibilities of enterprises, introduction of cutting-edge talents, etc.
Chairman Fang Tonghua said in the discussion that Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) in the current development, it has highly focused on drug innovation and research, focused on the scientific research and innovation of traditional Chinese medicine and biological medicine, and formed a highly competitive product pipeline integrating traditional Chinese medicine, chemical medicine and biological medicine based on the solid foundation of “industry university research” integration created by the enterprise. In the future, Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) will serve the people of the whole country with more products with high scientific and technological value and definite curative effect.
Vice governor Sun Dongsheng affirmed the achievements of Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) over the years and its contribution to the development of Longjiang, and hoped that Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) would firmly seize the opportunity of national support and encouragement for the development of traditional Chinese medicine and biopharmaceutical, and play a positive role in promoting the life and health of Longjiang people and the people of the whole country. We should further strengthen the control of the basic national policies, and finally realize the guidance of the policies with more responsibility and thinking. The government supports the company to strengthen the R & D and technical reserves of highly competitive varieties, introduce more cutting-edge talents, and play a leading role in local economic development Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) we should follow the requirements of innovation and creation, high quality and high-tech development put forward by the state, and continue to develop a large health industry with pharmaceutical R & D, production and sales as the core. Firmly grasp the historical opportunity that the party and the state attach importance to the inheritance of traditional Chinese medicine culture and the innovative development of the pharmaceutical industry, expand the layout of the health industry with new ideas, new technologies and new business forms, and contribute to the overall revitalization and all-round revitalization of Longjiang medical and health cause.
Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) its main business is the traditional Chinese medicine industry, and the sales of the main products of medical terminals have improved in recent years. According to authoritative statistics, 23 protected varieties of traditional Chinese medicine during the protection period had terminal sales of more than 100 million yuan in Chinese public medical institutions in the first half of 2021, of which 17 were exclusive products. Among the six non exclusive products, Xuesaitong (freeze-dried) for injection of Harbin Zhenbao Pharmaceutical ( Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) subsidiary) is a grade 2 protected variety. The sales of this product in the terminals of public medical institutions in China exceeded 900 million yuan in the first half of 2021, with a growth rate of 38.65%. The sales growth of Xueshuantong capsule, the exclusive product of Harbin Zhenbao pharmaceutical, has also been amazing in recent years. With the growth rate of 132.89%, the sales exceeded 100 million yuan for the first time in 2020, and there was still a 50.38% growth in the first half of 2021. This product has become another potential product of Heilongjiang Zbd Pharmaceutical Co.Ltd(603567) in the drug market for cardiovascular and cerebrovascular diseases, helping it speed up its market ranking.
